| ||||||||||||||
|
|
|||||||||||||


*Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center at Dallas;
Departments of Anesthesiology, Pathology, and Immunology, Washington University School of Medicine;
Department of Anesthesiology, University of Florida College of Medicine
Address correspondence and reprint requests to Charles Whitten, MD, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 753909068. Address e-mail to charles.whitten{at}utsouthwestern.edu
| Abstract |
|---|
|
|
|---|
(angle) was decreased from baseline in the DEX group. The changes in factor VIII, activated partial thromboplastin time, and TEG® measurements indicate that HES and DEX may attenuate the hypercoagulability related to surgery. IMPLICATIONS: Lactated Ringers solution, albumin, dextran, and hetastarch were compared as replacement fluids in an acute normovolemic hemodilution protocol in adult patients undergoing radical prostatectomy. Differences in coagulation measurements suggest that dextran and hetastarch may attenuate surgically induced hypercoagulability.
| Introduction |
|---|
|
|
|---|
ANH involves the removal of blood from the patient shortly after the induction of anesthesia and before the start of major surgical blood loss. A replacement fluid is simultaneously transfused to maintain intravascular volume. The stored blood is returned to the patient when a threshold hematocrit (Hct) is reached, or sooner, if clinically indicated. Ideally, this is after most of the blood loss has occurred.
Both crystalloid and colloid replacement fluids have been successfully used to maintain normovolemia during ANH. Colloids such as hetastarch and dextran decrease hypercoagulability in some studies (68), whereas crystalloid administration may not (9,10). Less is known about the effects of these fluids on hemostasis within the context of ANH. This prospective, randomized study was designed to determine if the replacement fluid choice impacts measured coagulation values and perioperative blood loss.
| Methods |
|---|
|
|
|---|
All patients were premedicated with midazolam in the preoperative holding area and received a standardized general anesthetic induction consisting of thiopental (34 mg/kg), vecuronium (0.1 mg/kg), and fentanyl (2.5 µg/kg). After tracheal intubation, anesthesia was maintained with isoflurane, nitrous oxide (67% in oxygen), and a continuous fentanyl infusion (13 µg · kg-1 · h-1).
All patients underwent moderate hemodilution to a target Hb of 9 g/dL. ANH was performed in conjunction with prepping and draping of the patient and pelvic lymph node dissection. Whole blood was collected in standard citrate-phosphate-dextrose (CPDA-1) blood collection bags while simultaneously infusing the replacement fluid. LR was administered in a 3:1 volume replacement ratio and the colloids in a 1:1 ratio. The colloid groups received a maximum of 20 mL/kg of the study fluid during hemodilution to adhere to the maximum recommended doses of HES and DEX. If further hemodilution was required to achieve the target Hb value in patients who received the maximum amount of colloid infusion, LR was used in a 3:1 ratio. The blood collected during hemodilution was returned to the patient when Hb <8 g/dL or when the attending anesthesiologist felt it was clinically indicated, primarily for persistent decreases in blood pressure. All hemodiluted blood was returned to the patient before leaving the operating room (OR). If Hb <8 g/dL in the operating room or during the hospital stay, any PAD was transfused, followed by allogeneic blood if required.
Blood samples for coagulation testing and Hb levels were collected before induction, preANH, postANH, and upon arrival to the recovery room (postanesthesia care unit [PACU]). Prothrombin time, activated partial thromboplastin time (aPTT), and fibrinogen concentration were determined on citrated plasma using an automated coagulation analyzer. Platelets were counted in EDTA-anticoagulated blood. Factor V and factor VIII activity was determined using a functional assay supplied by Diagnostica Stago (Asnieres, France). Celite-activated thromboelastography (TEG®) (Haemoscope Corp, Skokie, IL) was performed immediately after collecting each blood sample, and standard TEG® variables were obtained using software provided by the manufacturer. The primary investigator measured Ivy bleeding times before surgery and upon arrival to the PACU using a Simplate device (Organon Teknika Corp, Durham, NC). A complete blood count was drawn on postoperative Day 3 (POD 3) to estimate total perioperative RBC loss using the formula (where IBW is ideal body weight) (11):
|
|
|
|
|
|
Data were analyzed using SPSS for Windows software (release 6.1; SPSS, Inc, Chicago, IL). One-way analysis of variance was performed for all continuous variables. When a significant difference was noted, a Bonferroni test was performed for post hoc comparisons within and between groups. Nonparametric variables were analyzed using
2 testing. P values <0.05 were considered significant. Data are expressed as mean ± SD.
| Results |
|---|
|
|
|---|
|
|
|
|
0.05) as well as a decreased
angle relative to LR and ALB. HES demonstrated less of an overall influence on the TEG®. The MA for HES decreased relative to LR in the PACU, and the
angle was unchanged relative to an increase in the LR group. The LR and ALB results illustrate the expected TEG® findings of decreased coagulability after the induction of general anesthesia (preANH) then increased coagulability after surgical stress (postANH and PACU) (12,13).
|
| Discussion |
|---|
|
|
|---|
The choice of replacement fluid during hemodilution has varying effects on coagulation values. A larger decrease in factor VIII levels might have been expected in the HES and DEX groups based upon previous studies (1517). This effect may have been masked by the stress response to surgery, which tends to increase factor VIII (18,19), as seen in the LR and ALB groups. TEG® measurements demonstrate the interaction of DEX and platelets with an increase in coagulation time and decreased MA when compared with LR and ALB. HES also decreased MA relative to LR and ALB. The significant decrease in postANH reaction time in the LR group compared with the DEX group is in agreement with studies indicating that moderate hemodilution with crystalloid may not suppress surgery-induced hypercoagulability (10,13). This response seems to be blunted to some extent by HES and DEX because DEX has platelet antiaggregatory properties (8,17) and HES is felt to influence platelet activity via von Willebrand Factor and factor VIII (15). Although the three colloid solutions were normal saline based, no patients developed significant acidosis that might have contributed to coagulation changes. A recent study comparing normal saline and LR for fluid resuscitation was unable to find any differences in TEG® values or blood loss (20).
There was no significant difference in total RBC loss or transfusion requirements among groups. However, the trend for more surgical blood loss and hospitalization RBC loss in the DEX and HES groups may be important based on the hematologic findings in this study. The lack of achievement of statistical significance for these clinical outcomes may be related to a type II statistical error because of inadequate power for the small series enrollment in this study. The higher POD 3 Hct in the LR group compared with the HES group may have been caused by early diureses of crystalloid. Use of HES or DEX in ANH may be beneficial if reduced coagulability leads to decreased thromboembolic complications without significantly increasing perioperative blood loss. However, patients at risk for bleeding because of congenital (e.g., von Willebrands disease in up to 1% of the population) or acquired abnormalities (e.g., warfarin or clopidogrel) may be at risk for increased bleeding with HES or DEX. Whether patients would benefit from the administration of HES or DEX from the standpoint of limiting potential prothrombotic episodes after surgery again was not the purpose of this investigation. This could be more clearly delineated in future investigations.
There were limitations of this study design. There was no power analysis performed on a predetermined outcome marker because this was an initial survey of coagulation markers designed to direct future studies. Although the surgeon was blinded to the replacement fluid used, the primary investigator was not. However, this should not have affected the results of the coagulation studies. There was no nonhemodilution group included in the study. At Washington University, ANH is the standard of care for patients undergoing radical retropubic prostatectomy. It has essentially replaced PAD in these patients. ANH is an equally effective blood conservation strategy and is more cost-effective than PAD (1,5,21,22).
In conclusion, data from our hematologic analysis reveal that use of DEX and HES when compared with either LR or ALB can attenuate hypercoagulability. This is reflected by increased aPTT values, decreased TEG® MA and
angle values, and a reduction in the anticipated increase in factor VIII levels. This is paralleled by clinical data that demonstrated a trend towards increased bleeding in patients receiving these replacement fluids. The changes observed may be either beneficial or detrimental depending on the status of a given patient. For most of the patients who demonstrate perioperative hypercoagulability and who are at risk for development of thrombotic complications, administration of either DEX or HES may reduce the incidence of these complications. However, use of these fluids may also result in slightly more blood loss and transfusion in patients at low risk for bleeding. For the patient at risk for excessive perioperative bleeding, use of these fluids may lead to substantial increases in bleeding or transfusion. Further, larger studies that are adequately powered to examine bleeding and thrombotic outcomes are required to support our preliminary findings.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. Viuff, B. Lauritzen, A. E. Pusateri, S. Andersen, R. Rojkjaer, and P. I. Johansson Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(R)) Br. J. Anaesth., September 1, 2008; 101(3): 324 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mittermayr, W. Streif, T. Haas, D. Fries, C. Velik-Salchner, A. Klingler, and P. Innerhofer Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo Br. J. Anaesth., March 1, 2008; 100(3): 307 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mittermayr, W. Streif, T. Haas, D. Fries, C. Velik-Salchner, A. Klingler, E. Oswald, C. Bach, M. Schnapka-Koepf, and P. Innerhofer Hemostatic Changes After Crystalloid or Colloid Fluid Administration During Major Orthopedic Surgery: The Role of Fibrinogen Administration Anesth. Analg., October 1, 2007; 105(4): 905 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hitosugi, T. Saito, S. Suzuki, I. Kubota, E. Shoda, T. Shimizu, and Y. Oi Hydroxyethyl Starch: The Effect of Molecular Weight and Degree of Substitution on Intravascular Retention In Vivo Anesth. Analg., September 1, 2007; 105(3): 724 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Van der Linden and B. E. Ickx The effects of colloid solutions on hemostasis: [Les effets des solutions colloides sur l'hemostase] Can J Anesth, June 1, 2006; 53(6_suppl): S30 - S39. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Niemi, R. T. Suojaranta-Ylinen, S. I. Kukkonen, and A. H. Kuitunen Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth. Analg., April 1, 2006; 102(4): 998 - 1006. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|